Press Room

RDD Europe 2019

Start
Tuesday, May 07, 2019 - 09:00
End
Friday, May 10, 2019 - 17:00
Location: Lisbon, Portugal
Booth Number: Table nr. 64

RDD Europe 2019 will be held at the Estoril Congress Center in Portugal and Hovione will be present.

 

Hovione, together with Hovione Technology will present an interactive workshop session:
 

Fully Integrated Dry Powder Solutions

  • Wednesday, May 8th | 2:00pm, 3:15pm and 4:30pm – Room F7
  • Presented by: Beatriz Fernandes, M.Sc., Eunice Costa, Ph.D., João Ventura, Ph.D.and Maria Braga, Ph.D.

This session will review traditional and advanced formulation approaches for inhalation and nasal delivery, coupling key aspects across particle engineering as well as formulation and device design. Case studies will be presented focused on the interaction between traditional carrier-based formulation components and the final outcome in terms of aerodynamic performance, manufacturability and expected lung dose. Further case studies will look at carrier-free formulations for DPIs and for nasal applications, advanced particle engineering technologies applicable to labile biomolecules and finally design optimization of a cost-effective capsule-based inhaler and device development targeting high dose delivery.
 
Hovione will also have two Communications:
 
May 9, 2019 | 11:00 am

  • Spray Drying of Inhalable Biopharmaceuticals of Increasing Size and 3D Structure Complexity: From 30 to 250 kDa (Session 4: Poster in the podium)
    Diana Fernandes, M.Sc., Hovione, Loures, Portugal

 
May 10, 2019 |11:15 am

  • Continuous Processing: Challenging the Current Manufacturing Paradigm for Dry Powder Inhalers (Session 7: New Approaches to Inhalation Product Development and Production)
    Eunice Costa, Ph.D., Hovione, Loures, Portugal

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025